MASHINIi

MetaVia Inc..

MTVA.US | Research and experimental development on natural sciences and engineering

MetaVia Inc. (MTVA.US) is a technology company focused on developing and commercializing advanced materials and solutions for various industries. While specific details about their products and services are limited, they likely engage in research, development, and manufacturing activities related to...Show More

Ethical Profile

Mixed.

MetaVia Inc. is a clinical-stage biotechnology company focused on cardiometabolic diseases. Their lead drug candidates show promise: DA-1726 achieved a mean 4.3% weight loss in Phase 1, and DA-1241 reduced ALT by 22.8 U/L in Phase 2a. The company invested $21.6 million in R&D in 2024. However, critics point to the inherent reliance on animal testing in pharmaceutical development, which conflicts with "Kind to Animals" values. Reports suggest a lack of available information regarding drug price accessibility, worker respect, ethical sourcing, environmental impact, and business transparency.

Value Scores

Better Health for All20
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

20

MetaVia Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases. Its drug candidates, DA-1726 for obesity and DA-1241 for MASH, have shown positive clinical trial results. DA-1726 demonstrated a mean weight loss of 4.3% and a maximum of 6.3% at Day 26, along with significant glucose and waist circumference reductions.

1
DA-1241 showed liver-protective and glucose-regulating effects, including a mean ALT reduction of 22.8 U/L and a CAP score improvement of 23.0 dB/m.
2
Both candidates exhibited favorable safety and tolerability profiles in trials, with DA-1726 having mild, transient, and infrequent gastrointestinal side effects and no serious adverse events or treatment-related discontinuations.
3
DA-1241 was also well tolerated with no treatment-emergent adverse events leading to discontinuation, except for one case in the placebo group.
4
The company's R&D expenses increased from $9.2 million in 2023 to $21.6 million in 2024, reflecting a substantial investment in health innovation.
5
The Phase 1 trial for DA-1726 is randomized, double-blind, and placebo-controlled, enrolling healthy adults with a BMI between 30-45 kg/m2, with safety and tolerability as the primary endpoint.
6

Fair Money & Economic Opportunity

0

No evidence available to assess MetaVia Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence was found in the provided articles to assess MetaVia Inc. against any of the KPIs for Fair Pay & Worker Respect. The articles primarily detail financial results, clinical trial updates, and securities offerings, without mentioning employee compensation, working conditions, labor relations, or safety records.

Fair Trade & Ethical Sourcing

0

No specific quantitative data for MetaVia Inc. (MTVA.US) was found across any of the provided articles for fair trade certification share, audit frequency, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend.

1
While the company mentions commitments to responsible supply chain initiatives, including adherence to the Responsible Business Alliance (RBA) Code of Conduct and policies on ethical and responsible mineral sourcing, no measurable outcomes or specific figures are provided to assess performance against the KPIs.
2

Honest & Fair Business

0

No evidence was found in the provided article to assess MetaVia Inc. against any of the 'Honest & Fair Business' KPIs.

1
The article explicitly states it does not contain any quantitative data, regulatory actions, certifications, awards, comparisons, contradictions, or data gaps relevant to the requested metrics.
2

Kind to Animals

0

No evidence available to assess MetaVia Inc. on Kind to Animals.

No War, No Weapons

0

No evidence available to assess MetaVia Inc. on No War, No Weapons.

Planet-Friendly Business

0

No evidence was found in the provided articles to assess MetaVia Inc. (MTVA.US) against the 'Planet-Friendly Business' ethical value. The articles either contained no relevant data, returned an error, or focused on other companies and unrelated topics.

Respect for Cultures & Communities

0

No specific data or information regarding MetaVia Inc.'s respect for cultures and communities, including formal partnerships, community investments, cultural incident protocols, or local employment, was found in the provided articles.

1
The articles primarily focused on financial results and clinical trial updates, or explicitly stated that sustainability data was unavailable or could not be extracted.
2

Safe & Smart Tech

0

No information relevant to MetaVia Inc. (MTVA.US) or the 'Safe & Smart Tech' ethical value was found in the provided article.

1
Therefore, no KPIs could be scored.

Zero Waste & Sustainable Products

0

No specific, concrete data points were found in the provided articles regarding MetaVia Inc.'s (MTVA.US) performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.

1
The articles primarily focus on the company's financial results and clinical trial updates for its biotechnology products.
2
Articles that appeared to contain sustainability data were identified as pertaining to 'Meta Platforms, Inc.' (the social media company) despite some being mislabeled with 'MTVA.US' in their summaries, and thus were not used for scoring MetaVia Inc.
3

Own MetaVia Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.